PT-141 and HSDD: A Look at Bremelanotide's FDA Journey

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Bremelanotide (PT-141), marketed as Vyleesi, received FDA approval in 2019 for premenopausal women with acquired, generalized Hypoactive Sexual Desire Disorder (HSDD). Its mechanism involves melanocortin receptor agonism in the central nervous system, distinct from hormonal interventions, offering a novel approach to a complex condition.

Bremelanotide and the Path to FDA Approval for HSDD

Approximately 10% of adult women experience Hypoactive Sexual Desire Disorder (HSDD), characterized by a persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity, causing significant distress. Bremelanotide, known clinically as PT-141, emerged as a novel treatment, ultimately gaining FDA approval in June 2019 under the brand name Vyleesi for premenopausal women with acquired, generalized HSDD.

Understanding Bremelanotide's Mechanism of Action

Unlike hormonal therapies, PT-141 is a synthetic melanocortin receptor agonist. Specifically, it activates melanocortin 4 receptors (MC4R) and, to a lesser extent, MC3R in the central nervous system. This action is believed to modulate neural pathways involved in sexual arousal and desire. The melanocortin system plays a crucial role in various physiological functions, including energy homeostasis, inflammation, and sexual function. By targeting these receptors, PT-141 aims to restore the balance of neurochemicals that contribute to healthy sexual desire.

The Clinical Trials Supporting Vyleesi

The FDA approval was primarily based on two pivotal Phase 3, randomized, double-blind, placebo-controlled trials: Reconnect Study 1 (NCT02333071) and Reconnect Study 2 (NCT02338960). These studies enrolled over 1,200 premenopausal women with acquired, generalized HSDD. Participants self-administered 1.75 mg of bremelanotide via subcutaneous injection as needed, at least 45 minutes before anticipated sexual activity, and no more than once within 24 hours or eight times per month.

The primary endpoints for these trials were changes in the Female Sexual Function Index (FSFI) Desire Domain score and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) total score. In both studies, a significantly greater proportion of women treated with bremelanotide experienced an increase of at least 1.2 points in the FSFI Desire Domain score and a decrease of at least 3 or 4 points in the FSDS-DAO total score compared to placebo. For instance, in Reconnect Study 1, 25% of Vyleesi-treated patients showed a clinically meaningful improvement in desire compared to 17% on placebo. Similarly, 35% of Vyleesi patients reported a reduction in distress compared to 25% on placebo. These weren't massive shifts, but they were statistically significant, indicating a modest yet meaningful impact for some women.

Adverse Effects and Nuance in Efficacy

While effective for a subset of women, PT-141 isn't without its side effects. The most common adverse reactions reported in clinical trials included nausea (approximately 40% of patients), flushing (20%), injection site reactions (13%), and headache (11%). Nausea was often transient and mild to moderate, but it did lead to discontinuation in about 8% of patients. A transient increase in blood pressure and decrease in heart rate were also observed, typically resolving within 12 hours. This led to a contraindication for individuals with uncontrolled hypertension or known cardiovascular disease.

It's crucial to understand that PT-141 doesn't work for everyone. Its efficacy is often described as modest. This isn't a 'magic bullet' for all cases of HSDD, which can stem from a multitude of factors including relationship issues, psychological stressors, hormonal imbalances, and medication side effects. Vyleesi specifically targets acquired, generalized HSDD, meaning the HSDD developed after a period of normal sexual function and isn't limited to specific situations or partners. This distinction is vital; if a woman's HSDD is primarily due to a dysfunctional relationship, a melanocortin agonist won't address the root cause.

PT-141 vs. Flibanserin: A Comparative Look

When discussing pharmacological treatments for HSDD, a comparison with flibanserin (Addyi) is inevitable. Flibanserin, approved in 2015, is an oral medication taken daily, acting as a serotonin 1A receptor agonist and a serotonin 2A receptor antagonist. Its mechanism is often described as rebalancing neurotransmitters in the brain to improve sexual desire. However, flibanserin has its own set of challenges, including significant drug interactions (especially with alcohol, leading to severe hypotension and syncope) and a similar modest efficacy profile. A key difference lies in administration: flibanserin is a daily pill, while PT-141 is an on-demand subcutaneous injection. This 'as-needed' dosing can be appealing to some, offering more control and avoiding daily medication burden. However, the injectable route might be a deterrent for others. Both drugs highlight the complexity of treating HSDD and the need for individualized patient assessment.

Clinical Takeaway

For premenopausal women presenting with acquired, generalized HSDD causing significant distress, and after ruling out other contributing factors like hormonal deficiencies (e.g., estradiol < 50 pg/mL, testosterone < 20 ng/dL) or medication side effects, a trial of PT-141 (Vyleesi 1.75 mg subcutaneous injection as needed, up to 8 times per month) can be considered, provided they have no contraindications such as uncontrolled hypertension or cardiovascular disease, and are counseled on potential side effects like nausea and flushing.